Biblio Discovery — Demo Discovery Service

14 hasil untuk "Guo-He Lin"

Menampilkan 1–14 · 0,30 detik · RSS

  1. Artikel Jurnal

    The efficacy of adebrelimab compared with durvalumab and atezolizumab in untreated extensive-stage small-cell lung cancer: a survival analysis of reconstructed patient-level data

    Bi-Cheng Wang; Chen Fu; Guo-He Lin

    Frontiers in Immunology, Vol. 14 · 2023 · Inggris · DOAJ Scopus

    BackgroundAdebrelimab showed excellent efficacy in the first-line treatment for extensive-stage small-cell lung cancer (ES-SCLC). However, whether adebrelimab is superior to durvalumab and atezolizumab remains unclear. Therefore, we, in this study, aimed to compare the survival data of adebrelimab…

  2. Artikel Jurnal

    Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies

    Bi-Cheng Wang; Bo-Ya Xiao; Guo-He Lin

    BMC Cancer, Vol. 22 No. 1 · 2022 · Inggris · DOAJ Scopus

    Highlights 1. Nearly 44% of relapsed Ewing sarcoma patients achieved an ORR after IT treatment. 2. Relapsed Ewing sarcoma treated with IT had an over 66% DCR. 3. IT chemotherapy caused low incidences of neutropenia, thrombocytopenia, and diarrhea in treating relapsed Ewing sarcoma.

  3. Artikel Jurnal Teks lengkap

    The efficacy and tolerability of combining pemetrexed-based chemotherapy with gefitinib in the first-line treatment of non-small cell lung cancer with mutated EGFR: A pooled analysis of randomized clinical trials

    Bi-Cheng Wang; Wen-Xuan Zhang; Bo-Hua Kuang dkk.

    PLOS ONE, Vol. 17 No. 10 · 2022 · Inggris · PLOS Scopus

    Background: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) monotherapy is the standard of care in treating advanced non-small cell lung cancer (NSCLC). Nevertheless, whether adding pemetrexed-based chemotherapy to EGFR-TKI targeted therapy furtherly prolongs survival…

    Juga tersedia di: DOAJ, DOAJ

  4. Artikel Jurnal

    Durvalumab and pembrolizumab in advanced biliary tract cancer: a reconstructed patient-level mimic head-to-head comparative analysis

    Bi-Cheng Wang; Bo-Hua Kuang; Guo-He Lin dkk.

    Frontiers in Immunology, Vol. 15 · 2024 · Inggris · DOAJ Scopus

    BackgroundThe addition of durvalumab or pembrolizumab to gemcitabine and cisplatin (GP) has been approved to statistically improve survival outcomes in patients with advanced biliary tract cancer. However, since the survival time was only prolonged by about two months, doubts have been raised. In…

  5. Artikel Jurnal

    Emerging chemotherapy-based treatments in anaplastic thyroid cancer: an updated analysis of prospective studies

    Bi-Cheng Wang; Guo-He Lin; Bo-Hua Kuang dkk.

    Frontiers in Endocrinology, Vol. 15 · 2024 · Inggris · DOAJ Scopus

    BackgroundFor patients with anaplastic thyroid cancer (ATC) without mutational driver genes, chemotherapy is suggested to be the first-line treatment option. However, the benefits of chemotherapy in treating ATC are limited. In this analysis, we collected the prospective data reported since 2010 to…

  6. Artikel Jurnal

    The efficacy and safety of induction chemotherapy combined with concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in nasopharyngeal carcinoma patients: a systematic review and meta-analysis

    Bi-Cheng Wang; Bo-Ya Xiao; Guo-He Lin dkk.

    BMC Cancer, Vol. 20 No. 1 · 2020 · Inggris · DOAJ Scopus

    Abstract Background Induction chemotherapy (IC) combined with concurrent chemoradiotherapy (CCRT) has been recommended as the first-line therapy for locoregional nasopharyngeal carcinoma (NPC). Due to the different chemotherapeutic drugs used in the IC and CCRT, the results remain controversial…

  7. Artikel Jurnal

    Induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma: A systematic review and meta-analysis

    Bi-Cheng Wang; Bo-Hua Kuang; Xin-Xiu Liu dkk.

    Frontiers in Oncology, Vol. 12 · 2022 · Inggris · DOAJ Scopus

    BackgroundAdding induction chemotherapy to concurrent platinum-based chemoradiotherapy has significantly prolonged the survival time of patients with locoregionally advanced nasopharyngeal carcinoma. In this study, we intend to evaluate the survival outcomes, responses, and incidences of toxicities…

  8. Artikel Jurnal

    Doxorubicin/Adriamycin Monotherapy or Plus Ifosfamide in First-Line Treatment for Advanced Soft Tissue Sarcoma: A Pooled Analysis of Randomized Trials

    Bi-Cheng Wang; Bo-Hua Kuang; Bo-Ya Xiao dkk.

    Frontiers in Oncology, Vol. 11 · 2021 · Inggris · DOAJ Scopus

    BackgroundDoxorubicin/Adriamycin (ADM) alone or combined with ifosfamide (IFO) (AI) is available for previously untreated advanced soft tissue sarcoma (ASTS). However, the clinical choice between them remains controversial. In this pooled analysis, we comprehensively compared the efficacy and…

  9. Artikel Jurnal Teks lengkap

    A Bayesian network meta-analysis of the primary definitive therapies for locoregionally advanced nasopharyngeal carcinoma: IC+CCRT, CCRT+AC, and CCRT alone

    Zhan-Jie Zhang; Liang-Liang Shi; Xiao-Hua Hong dkk.

    PLOS ONE, Vol. 17 No. 3 · 2022 · Inggris · PLOS Scopus

    Background: The major aim of this Bayesian network analysis was to determine the optimal treatment strategy for locoregionally advanced nasopharyngeal carcinoma (LANPC). Method: We systematically searched databases and extracted data from randomized clinical trials involving LANPC patients randomly…

    Juga tersedia di: DOAJ, DOAJ

  10. Artikel Jurnal

    Tyrosine kinase inhibitors in patients with advanced anaplastic thyroid cancer: an effective analysis based on real-world retrospective studies

    Bo-Hua Kuang; Wen-Xuan Zhang; Guo-He Lin dkk.

    Frontiers in Endocrinology, Vol. 15 · 2024 · Inggris · DOAJ Scopus

    BackgroundTyrosine kinase inhibitors (TKIs) contribute to the treatment of patients with anaplastic thyroid cancer (ATC). Although prospective clinical studies of TKIs exhibit limited efficacy, whether ATC patients benefit from TKI treatment in real-world clinical practice may enlighten future…